Retatrutide is an investigational once-weekly injectable drug that helped patients shed roughly a quarter of their body weight in trials results that approach the effectiveness of bariatric surgery
The bottom line GLP-1 medications are genuinely life-changing but the skin changes they bring, especially on the body, deserve real attention and real solutions
What this means for dosing calculations: the clinical trial protocols use fixed escalation schedules with specific dose targets (typically 8mg or 12mg maintenance)
Supplementary Information 12916_2025_4200_MOESM1_ESM.docx (download DOCX Additional file 1: Tables S1S4
The idea is straightforward: semaglutide handles the GLP-1 pathway, while cagrilintide adds amylin-family satiety and post-meal glucose biology
They're usually prohibited from making "essentially" copies of available approved drugs, according to federal law, but they can do it if the original drug is in short supply